Table 1.

Key preclinical differences between the Tumor-Vascular Disrupting Agents (Tumor-VDAs) and anti-angiogenic drug classes.

Tumor-VDAs	Anti-angiogenic agents
Administered acutely	Administered chronically
Disrupt the established tumor vasculature	Inhibit neovascularization
Cause vessel occlusion and inhibition of blood flow	Induce vascular normalization with initial improved tumor blood flow
Cause extensive tumor necrosis	Prevent or limit tumor growth
Particularly active against large tumor masses, causing extensive central necrosis	Particularly active in peripheral tumor locations where nascent vessels are more predominant